NCT06556173: An ongoing trial by Zomagen Biosciences, Ltd
This trial is ongoing. It must report results 3 months, 2 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06556173 |
|---|---|
| Title | A Phase 2a, Single Site, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VTX3232 in Participants With Early-Stage Parkinson's Disease |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Aug. 8, 2024 |
| Completion date | April 4, 2025 |
| Required reporting date | April 4, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |